Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

NSCLC Stage IV Clinical Trial

Official title:

Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03594682
• Other study ID #: HB-B001
• Status: Not yet recruiting
• Phase: N/A
• Start date: August 2018
• Est. completion date: July 2020

Study information

• Verified date: June 2018
• Source: Beijing Chest Hospital
• Contact: Hu Ying
• Phone: 010-89509330
• Email: huying2004[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and efficacy of two different administration methods of apatinib in NSCLC patients.

Description:

1. Aged ≥18；

2. Locally advanced/metastatic non-small lung cancer (IIIb/IV) confirmed by pathology with measurable lesions；

3. Patients with wild type EGFR/ALK must received two kinds of systemic chemotherapy before；Patients with EGFR mutation positive had experienced treatment failure with TKI in first line and Chemotherapy in second line ；

4. ECOG：0-4；

5. The subjects were treated with other drugs has been restored (NCI CTCAE version 4.0 class 1 or less), which accept nitroso urea or mitomycin interval 6 weeks or more; Accept other cytotoxic drugs, bevacizumab (Avastin) (except local palliative radiotherapy), radiotherapy or surgery four weeks or more. EGFR TKI ≥2 weeks; Main organs function is normal；

6. Fertile woman must perform a pregnancy test (serum or urine) 7 days before screened, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib. For man, surgical sterilization should be performed, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib；

7. Patients voluntarily entered the study and signed informed consent form (ICF).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 31
• Est. completion date: July 2020
• Est. primary completion date: July 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Aged =18;

2. Locally advanced/metastatic non-small lung cancer (IIIb / IV) confirmed by pathology with measurable lesions ;

3. Patients with wild type EGFR/ALK must received two kinds of systemic chemotherapy before;Patients with EGFR mutation positive had experienced treatment failure with TKI in first line and Chemotherapy in second line ;

4. ECOG:0-4;

5. The subjects were treated with other drugs has been restored (NCI CTCAE version 4.0 class 1 or less), which accept nitroso urea or mitomycin interval 6 weeks or more; Accept other cytotoxic drugs, bevacizumab (Avastin) (except local palliative radiotherapy), radiotherapy or surgery four weeks or more. EGFR TKI =2 weeks; Main organs function is normal;

6. Fertile woman must perform a pregnancy test (serum or urine) 7 days before screened, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib. For man, surgical sterilization should be performed, or voluntarily adopt proper methods of contraception during the observation period and 8 week after the last given apatinib;

7. Patients voluntarily entered the study and signed informed consent form (ICF).

Exclusion Criteria:

1. brain MRI, CT or venography confirmed that there are brain hemorrhage symptoms;

2. Tumor invade big vessels or close to big vessels (less than 5mm);

3. Patients with uncontrollable hypertension (systolic blood pressure> 140 mmHg, diastolic blood pressure> 90 mmHg, despite optimal drug therapy).;

4. Patients with with grade ? myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male = 450 ms, female =470 ms);

5. Abnormal coagulation (INR>1.5 or PT>ULN+4, or APTT>1.5 ULN), bleeding tendency or receiving coagulation therapy

6. Urine protein=++, or urine protein in 24 hours=1.0g

7. CTCAE 2 degrees or more peripheral neuropathy, except the trauma;

8. Unhealed bone fracture or wound for long time;

9. Patients who received systemic antibiotic treatment of serious infections;

10. Decompensated diabetes or high dose of glucocorticoid treatment other banned disease;

11. Patients with active hepatitis B virus or hepatitis c virus infection;

12. Patients with obvious factors affecting absorption of oral drugs, such as difficulties in swallowing, chronic diarrhea and intestinal obstruction, etc.

13. Received big surgery, had bone fracture or ulcer in 4 weeks.

14. Within 6 weeks before random severe weight loss (> 10%);

15. Patients who experienced bleeding symptoms of clinical significance within 3 months before screening, or with confirmed bleeding tendency such as hemorrhage of digestive tract, hemorrhagic gastric ulcer, baseline occult blood in stool ++ and above, or vasculitis, etc;

16. Random 12 months before the artery/vein thrombosis events, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.;

17. Known history of hypersensitivity to apatinib or any of it components.

Related Conditions & MeSH terms

• NSCLC Stage IIIB
• NSCLC Stage IV

Intervention

Other:
• Intervention/treatment
experimentalgroup initial dose: 250mg qod 250mg qd/500mg qd by turn 500mg qd control group: 750mg qd

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Beijing Chest Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	duration of treatment	time from take apatinib to withdrawal from experiment due to adverse reaction of apatinib	two years